APONTIS PHARMA
APONTIS PHARMA is a bridge builder connecting various players in the healthcare sector with a focus on innovative single-pill therapies. The company aims to establish Single Pill as the gold standard for better life, ensuring high therapeutic success and minimizing costs. With a long-standing reputation in Germany, it develops and markets combination products for cardiovascular diseases, supporting physicians with consulting services and training. Its mission is to improve patient care through high-quality, innovative medicines and strategic partnerships, focusing on expanding its portfolio of Single Pills and benefiting millions of patients. The company emphasizes good corporate governance, transparency, and long-term sustainable development, with a strong commitment to building trust with stakeholders.
Industries
Nr. of Employees
medium (51-250)
APONTIS PHARMA
Rolf-Schwarz-Schütte-Platz 1, 40789 Monheim am Rhein, Germany
Products
Fixed‑dose combination oral tablet — amlodipine + atorvastatin
Oral fixed‑dose tablet combining a calcium channel blocker and an HMG‑CoA reductase inhibitor for cardiovascular risk management; launched 2022 (marketed in Germany).
Fixed‑dose combination oral tablet — atorvastatin + ezetimibe
Oral fixed‑dose tablet combining an HMG‑CoA reductase inhibitor and a cholesterol absorption inhibitor for lipid lowering; launched 2019.
Fixed‑dose combination oral tablet — amlodipine + bisoprolol fumarate
Oral fixed‑dose tablet combining a calcium channel blocker and a beta‑blocker for hypertension management; launched 2017.
Fixed‑dose combination oral tablet — candesartan + indapamide
Oral fixed‑dose tablet combining an angiotensin receptor blocker and a thiazide‑like diuretic for blood pressure control; listed with 2025.
Fixed‑dose combination oral tablet — candesartan + amlodipine
Oral fixed‑dose tablet combining an angiotensin receptor blocker and a calcium channel blocker for hypertension; originally launched 2015 (and variants updated 2023).
Fixed‑dose combination oral tablet — acetylsalicylic acid + atorvastatin + ramipril
Three‑agent oral fixed‑dose combination intended for cardiovascular risk management; listed with 2017.
Fixed‑dose combination oral tablet — amlodipine + atorvastatin
Oral fixed‑dose tablet combining a calcium channel blocker and an HMG‑CoA reductase inhibitor for cardiovascular risk management; launched 2022 (marketed in Germany).
Fixed‑dose combination oral tablet — atorvastatin + ezetimibe
Oral fixed‑dose tablet combining an HMG‑CoA reductase inhibitor and a cholesterol absorption inhibitor for lipid lowering; launched 2019.
Fixed‑dose combination oral tablet — amlodipine + bisoprolol fumarate
Oral fixed‑dose tablet combining a calcium channel blocker and a beta‑blocker for hypertension management; launched 2017.
Fixed‑dose combination oral tablet — candesartan + indapamide
Oral fixed‑dose tablet combining an angiotensin receptor blocker and a thiazide‑like diuretic for blood pressure control; listed with 2025.
Fixed‑dose combination oral tablet — candesartan + amlodipine
Oral fixed‑dose tablet combining an angiotensin receptor blocker and a calcium channel blocker for hypertension; originally launched 2015 (and variants updated 2023).
Fixed‑dose combination oral tablet — acetylsalicylic acid + atorvastatin + ramipril
Three‑agent oral fixed‑dose combination intended for cardiovascular risk management; listed with 2017.
Services
Partnerships to jointly promote and commercialize prescription medicines in Germany through shared sales and marketing activities.
Evaluation, negotiation and execution of licensing deals to acquire rights to market products or to out-license assets.
Provision of targeted promotional services for third parties on a fee‑for‑service basis.
Medical education and consulting services for physicians provided by qualified pharmaceutical consultants to support product use and individualized treatment, delivered on-site and via digital channels.
Channels for receiving adverse event and product quality reports and for directing reporters to the appropriate regulatory contacts.
Preparation and dissemination of financial reports, prospectus and capital markets disclosures, maintenance of a financial calendar, AGM documentation and investor mailings for investors, analysts and regulatory stakeholders.
Partnerships to jointly promote and commercialize prescription medicines in Germany through shared sales and marketing activities.
Evaluation, negotiation and execution of licensing deals to acquire rights to market products or to out-license assets.
Provision of targeted promotional services for third parties on a fee‑for‑service basis.
Medical education and consulting services for physicians provided by qualified pharmaceutical consultants to support product use and individualized treatment, delivered on-site and via digital channels.
Channels for receiving adverse event and product quality reports and for directing reporters to the appropriate regulatory contacts.
Preparation and dissemination of financial reports, prospectus and capital markets disclosures, maintenance of a financial calendar, AGM documentation and investor mailings for investors, analysts and regulatory stakeholders.
Expertise Areas
- Fixed‑dose combination (single‑pill) product development
- Cardiovascular therapeutics
- Pharmaceutical licensing and business development
- Marketing and commercialization for primary care and specialists
Key Technologies
- Oral fixed‑dose combination formulation
- Licensing and commercialization frameworks
- Field sales CRM and physician engagement platforms
- Pharmacovigilance intake and reporting systems
News & Updates
APONTIS PHARMA publishes Q1 2025 results
The company announced its financial results for the first quarter of 2025, confirming its growth trajectory.
Strategic partnership with a biotech firm
A new collaboration to develop innovative treatments for chronic diseases.
Interview with CEO Bruno Wohlschlegel
Insights into the company's strategy and future plans.
Market analysis of Single Pill therapies
An overview of the market potential and competitive landscape.
High reputation among prescribers in Germany
Recognized for well-established access to approximately 23,500 physicians.
Successful market launch of eleven Single Pills since 2013
Treating hundreds of thousands of patients with innovative therapies.
APONTIS PHARMA publishes Q1 2025 results
The company announced its financial results for the first quarter of 2025, confirming its growth trajectory.
Strategic partnership with a biotech firm
A new collaboration to develop innovative treatments for chronic diseases.
Interview with CEO Bruno Wohlschlegel
Insights into the company's strategy and future plans.
Market analysis of Single Pill therapies
An overview of the market potential and competitive landscape.
High reputation among prescribers in Germany
Recognized for well-established access to approximately 23,500 physicians.
Successful market launch of eleven Single Pills since 2013
Treating hundreds of thousands of patients with innovative therapies.